UNSC Marine Expeditionary Reconnaissance

"Les peuples comme les astres ont le droit d’éclipse. Et tout est bien, pourvu que la lumière revienne et que l’éclipse ne dégénère pas en nuit."

- Les Misérables (1862), Myrmidon Program motto

The Myrmidon Program, formally known as SPARTAN Detachment IV, was an advanced special operations force operated by the UNSC Office of Naval Intelligence and the UNSC Special Operations Command. Instigated in 2578, the Myrmidon initiative was the "second epoch" of the SPARTAN Program, integrating novel biological augmentations, warfighting technologies, and combat philosophies to create futuristic special forces that fulfilled the UNSC's requirement for advanced special forces to enable mankind's survival in an evolving and demanding galaxy.

Overview
The Myrmidon Program was an expansive umbrella program operated by the UNSC Office of Naval Intelligence and UNSC Special Operations Command, and encompassed all aspects of the Myrmidon forces, including their formation, training, guidance, and direction, and also encompasses their auxiliary support staff.

The Myrmidons, the fourth iteration of the SPARTANs, drew from nearly one century of SPARTAN warfare and lessons learned from all three previous SPARTAN battalions. Because the previous SPARTAN programs served as the conceptual precedent for the program; namely, the training of augmented child soldiers as commandos, formally, the Myrmidons are known as "SPARTAN Detachment IV", assigned to UNSC Special Warfare Group SPARTAN.

However, the novel conceptual advances that have enabled the Myrmidons are strikingly different from the core values of the previous SPARTAN programs, and thus, many in the UNSC Office of Naval Intelligence often label Myrmidons separate from the SPARTANs because of their numerous differences. However, the UNSC Special Operations Command Order of Battle (OB) integrates the Myrmidons into the former SPARTAN command organizational hierarchy.

Casus genesis
The causation of the formation of the Myrmidons, their casus genesis, lay simply in the state of galactic affairs — at the time of their formation, it was the 2580s; the UNSC had substantially changed in the three decades that had passed since 2552 and the closure of the Human-Covenant War.

Organization
The Myrmidon Program has a highly atypical command structure and internal organization. One of the major design philosophies of the Myrmidons was counterterrorism; the usage of a small number of highly-trained elite light infantry for highly-intensive counterterror and counterinsurgency operations.

Thus, the Myrmidon Program as of 2590 maintained only one company of infantry, numbering approximately one hundred strong. While this was an extremely small number of operators for any conventional special forces group, it was in accordance with the UNSC's need for a covert and specialized counterterrorism task force.

The ideation of the Myrmidons began with Kawika Son and Beah Schore, who both drew heavily from the success of Kimberly Ivy Blackburn, who indeed served as the proof of concept for the Myrmidon Program. Dr. Schore would only participate in the planning and initiation of the Myrmidons, his lack of military experience and his pacifistic ideals making him unable to participate in the active military mobilization of the Myrmidons. Son would be heavily involved in the creation, training, and the mobilization of the Myrmidons; this would earn him a senior position within the Myrmidon command structure.

Command Detachment
The position of Senior Commander, Myrmidon Detachment was traditionally held by a three-star Vice Admiral ( O-9 ). The detachment's senior commander was responsible for the training, oversight, direction, and operation of the entire Myrmidon unit as a whole, including its command, mobility, and support elements, and would be a member of the Headquarters & Headquarters Company (HHC) of the Myrmidons. The remainder of the HHC section was primarily comprised with the primary staff officers and their staffs, along with the staff officers of the support and auxiliary elements.

The first commander of the Myrmidon Detachment was Vice Admiral Kawika Son, Commander-in-Chief, UNSC Naval Special Warfare Command and a flag officer of the UNSC Navy. Son would begin his tenure as the Myrmidon unit's commander in 2578 as a two-star Rear Admiral, and would relinquish his command in 2600, several years after the closure of the devastating Beyond Veil's Azure crisis.

Mobility Detachment
The actual Myrmidon infantry company proper, known as the "mobility detachment", was approximately one hundred Myrmidons strong, and was responsible for prosecution of the unit's special warfare missions in the field.

The mobility detachment would be commanded by a Navy Captain ( CAPT, O-6 ), the company commander, and a Master Chief Petty Officer ( MCPO, E-9 ), who would serve as unit's senior enlisted NCO.

The remainder of the hundred-odd company was divided into four operational squadrons, Myrmidon Squadron ALPHA ("A"), Myrmidon Squadron BRAVO ("B"), Myrmidon Squadron CHARLIE ("C"), and Myrmidon Squadron DELTA ("D"). Each squadron was comprised of between twenty to thirty operators. The operational squadron was the fundamental deployment unit of the Myrmidons; typically, Myrmidons units were deployed to their respective theater of operations in the squadron-size formation.

Each operational squadron was under the leadership of a Navy Commander ( CMDR, O-5 ) and the squadron's senior enlisted, a Chief Petty Officer ( CPO, E-7 ). While the O-5 would serve as the squadron's commanding officer (CO) and the E-7 would serve as the squadron chief, the two were augmented by a squadron executive officer (XO), typically a Navy Lieutenant ( LT, O-3 ), and a squadron operations officer, typically a Lieutenant, Jr. Grade ( LTJG, O-2 ). The remaining fifteen to twenty-five operators were generally enlisted, special warfare specialists between the ranks of Petty Officer Third Class ( PO3, E-4 ) and Petty Officer First Class ( PO1, E-6 ), although there were a few exceptions.

Beneath the squadron-level formation, their hierarchical organization was not formally defined; instead, sub-squadron units were formed to meet mission requirements. While the majority of missions required either individual Myrmidons solo or a Myrmidon fire team (two-three operators), larger missions employed Myrmidon squads (four-six operators) or whole Myrmidon troops (eight-twelve operators).

A single operation, no matter on what scale, almost never could employ an entire squadron in the field — however, regular squadron-integration exercises were continually scheduled so that the entire squadron could perform as a cohesive warfighting unit, should massive open warfare arise.

All four Myrmidon squadrons were "direct action" capable, that is, that they fulfilled elite counterterrorism and counterinsurgency roles within the UNSC Special Operations Command, practicing even advanced special operations such as in extremis hostage rescue. However, all squadrons carried a secondary certification to further augment the infantry company as a whole. Myrmidon Squadron ALPHA ("A") and Myrmidon Squadron BRAVO ("B") was specially certified for heavy assault, Myrmidon Squadron CHARLIE ("C") was specially certified for dedicated reconnaissance roles, and Myrmidon Squadron DELTA ("D") was specially certified for covert action.

Support Detachment
The Myrmidon Support Detachment was an integral component of the Myrmidon Detachment, typically commanded by a Marine Corps Colonel ( COL, O-6 ).

The Myrmidon operators were extensively supported on all levels; the individual level, the team level, the squadron level, and the company level. The unit, with its high operations tempo (OPTEMPO), invariably required extensive auxiliary support to continue sustained operations. The Support Detachment was comprised of a Special Operations Air Wing, a Logistical Detachment, an Intelligence Detachment, a Training Detachment, a Communications Detachment, and a Medical Detachment.

The Special Operations Air Wing (SOAW) was responsible for operating attack and transport aviation assets in support of the Myrmidons, and was comprised of elite pilots, technicians, and ground crews from the UNSC Army's Reconnaissance Aviation Expeditionary Force (RAVEN) and also elite UNSC Navy squadrons. The Air Wing was directed by a Navy Captain ( CAPT, O-6 ) from the naval starfighter community.

The Logistical Detachment was responsible for the continued resupply and rearmament of the Myrmidons, and was integral to the sustained deployment of the Myrmidons across the myriad battlefields of the Milky Way Galaxy; it was commanded by a Marine Corps Lieutenant Colonel ( LTCOL, O-5 ).

The Myrmidon unit operated its own independent Intelligence Detachment; on most operations, the Myrmidons received extensive intelligence support. The Myrmidon Intelligence Detachment was strongly affiliated with the UNSC Office of Naval Intelligence, with high-confidence ONI intelligence supporting most Myrmidon field actions. The intelligence section was led by an ONI Commander ( CMDR, O-5 ).

Augmentations
The Myrmidon augmentation philosophy was highly nestled with an advanced understanding of human developmental biology and chemical biology.

An extensive knowledge of mammalian and human developmental biology and stem cell biology allowed for the manipulations of the in utero human embryo, allowing for extensive modifications of the child soldiers prior to birth.

A chemical biology approach was employed for the augmentation regiment, utilizing small-molecule probes to specifically perturb specific biological targets to produce defined phenotypic effects. The usage of small-molecule chemical compounds opposed to biological agents (i.e. peptides or recombinant vectors) maximized the safety of Myrmidon augmentation as well as its reproducibility from human to human. Computational modeling of chemical systems was substantially simpler than modeling of biological factors, which were invariably multiplex, simplifying modeling of chemical modifications of each human subject.

The Myrmidon philosophy advocates the use of small molecule compounds as chemical perturbers of biological activity at the embryonic, postnatal, and continual adult stages of life. Chemical agonists and inhibitors are used to provide precise, quantifiable, dose-responsive control over human physiology, with known biological targets and controllable side effects.

Phase I: Inhibition of embryonic stem cell (ESC) differentiation
Ten small-molecule chemical compounds (mostly protein kinase inhibitors), A-83-01 (Activin/TGFβ inhibitor), CHIR99021 (GSK3α/β inhibitor), SU5402 (FGFR1 inhibitor), Dorsomorphin (BMP inhibitor), Pluripotin (RasGAP, ERK1/2 inhibitor), Y-27632 (RacA, ROCK inhibitor), PD184352 (MKK1, MAPK/ERK inhibitor), Reversine (polypharmacological), Theanine (polypharmacological), and Flurbiprofen (polypharmacological) were combinatorially applied through in utero catherization during the first several days of pregnancy after insemination and zygote fertilization during the generation of the pluripotent inner cell mass (ICM) of the blastocyst and the formation of embryonic stem (ES) cells. All seven small-molecule compounds block differentiation signals or block apoptosis, thus promoting the intrinsic proliferation, pluripotency, and self-renewal transcriptional programming in ES cells, promoting the generation of a substantially enlarged pluripotent progenitor pool for downstream differentiation.

Receptor tyrosine kinase inhibitors

 * A-83-01 ( 3-(6-Methylpyridin-2-yl)-1-phenylthiocarbamoyl-4-quinolin-4-ylpyrazole ): Chemical inhibitor of certain Type I TGFβ Receptors, including the activin receptor (ALK4), the TGF-β receptor (ALK5), and the nodal receptor (ALK7).  In human and murine development, TGFβ family signals induce the differentiation of embryonic stem (ES) cells to the definitive endoderm.    Blockade of TGFβ signals by A-83-01 for several days represses endodermal differentiation and maintains the pluripotent state of human embryonic stem cells formed by the zygote.


 * Dorsomorphin / Compound C ( 6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine ): Specific inhibitor of ALK2, ALK3, and ALK6, protein tyrosine kinase (PTK) inhibitors of members of the ALK1 and ALK3 families of type I TGFβ Receptors, inhibiting the transmission of BMP2, BMP4, BMP6, and BMP7 cytokine signals and BMP signaling and subsequent SMAD phosphorylation. BMP signals in the embryo are responsible for gastrulation, mesodermal specification, and chrondrogenesis and also dorsal-ventral patterning and dorsalization, thus the blockade of type I TGFβ receptors leads to neutralization of mesodermal differentiation and enhances the pluripotent ES state.


 * SU5402 ( 3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone ): Small-molecule chemical inhibitor of fibroblast growth factor receptor 1 (FGFR1) protein tyrosine kinase (PTK), showing specificy for FGFR1 without inhibition of the insulin receptor (INSR) nor the platelet-derived growth factor receptor (PDGFR). Small molecule compound of the indolinone classification, with organic-templated synthesis to generate a library for high-throughput screening, inhibiting FGFR1K auto-phosphorylation and FGF2-induced MEK/ERK signaling and DNA replication in molecular assays of fibroblasts. SU5402's molecular mechanism of action is well-documented; it binds to the ATP-binding site on FGFR1, actively competing with ATP instead of the FGF substrate, and it interacts with FGFR1 on a molecular scale by three separate intermolecular interactions with the kinase domain, being sheltered by its hydrophobic haven, and it demonstrates even electron distribution. FGF2 and FGF4 are two extrinsic cytokines responsible for ES differentiation through activation of the protein kinase B (PKB) and MEK/ERK signaling pathways to induce mesodermal germ specification and neuronal fating of neuroectoderm differentiation, and FGFR1 blockade by SU5402 inhibits ES differentiation.

Signaling kinase inhibitors

 * CHIR99021 ( 6-(2-(4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-ylamino)ethylamino)nicotinonitrile ): Small-molecule chemical inhibitor of GSK3α/β, demonstrating >500-fold selectivity for biological target over a panel of over thirty protein kinases and non-kinase enzymes . GSK3β is a biological inhibitor of Wnt signaling, and Wnt signaling is an active intracellular signaling pathway in both human and mouse embryonic stem cells, where Wnt signaling is implicated in stem cell self-renewal, and Wnt signals control ESC cell cycle and expression of ES transcription factors and transcriptional regulators, such as Oct4, Nanog, and Rex1, thus implicating Wnt signaling in ES self-renewal and proliferation. . CHIR99021 application through the first several days of pregnancy after artificial insemination was used to specifically promote the intrinsic ESC pluripotency program through coupled signaling and transcriptional mechanisms.


 * Y-27632 [ (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride ]: Specific small-molecule inhibitor of p160-Rho-associated coiled-coil kinase (ROCK) The ROCK kinases are responsible for cell cycle regulation and control of apoptosis While the molecular mechanisms are not completely understood, Y-27632 blockade of RhoA and ROCK signaling promotes the survival of dissociated human embryonic stem (hES) cells and also their survival in suspension culture without attachment, likely by inhibiting chemically-induced apoptosis. Y-27632 was administered in order to promote self-renewal of hES cells in the inner cell mass.


 * PD184352 ( 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) ): Specific small-molecule inhibitor of mitogen-activated protein kinase kinase (MKK1), thus inhibiting ERK/MAPK signaling and inhibiting differentiation-inducing ERK signals in embryonic stem cells.


 * SB203580 ( 4-(4´-fluorophenyl)-2-(4´-methylsulfinylphenyl)-5-(4´-pyridyl) imidazole ): Specific small-molecule inhibitor of members of the p38 mitogen-activated protein kinase (MAPK) family, including isoforms p38α, p38β, and p38β2, shown to support embryonic stem cell self-renewal similar to bone morphogenetic protein 4 (BMP4) application and to functionally substitute for the requirement of BMP signaling in ES self-renewal.

Polypharmacological

 * Pluripotin / SC1 ( N-(3-(7-(1,3-dimethyl-1H-pyrazol-5-ylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-d]pyrimidin-3(4H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide ): Specific polypharmacological small-molecule compound that is a dual specific inhibitor of RasGAP and ERK1/2, dually promoting ES self-renewal and inhibiting FGF-induced differentiation, capable of sustaining mouse embryonic stem cells (mES) in chemically-defined feeder free in vitro cell culture conditions. Thus, in utero application of pluripotin to the developing embryo antagonizes differentiation and promotes self-renewal and proliferation.


 * Reversine / RV ( 2-(4-morpholinoanilino)-N6-cyclohexyladenine ): 2,6-disubstituted purine heterocycle that is a polypharmacological small-molecule compound with incompletely-characterized biological targets, including but not limited to Aurora kinases A and B, Adenosine receptor A3, MEK1, and myosin II heavy chain Induces chemically-defined de-differentiation of myoblasts into mesodermal and neuroectodermal lineages, inducing upregulation of neuroectodermal and mesodermal transcription factors while causing epigenetic silencing of myocyte transcription factor MyoD, and also phenotypic conversion into a putative mesenchymal stem cell-like intermediate  . Reversine is used to de-differentiate pre-emptively differentiating cells into a pluripotent progenitor state and maintaining ES self-renewal pool.


 * Theanine ( 2-amino-4-(ethylcarbamoyl)butyric acid ): Small-molecule compound derived from pharmacognosy and natural sources (Camellia sinensis and Boletus badius) that is a psychoactive agent of uncharacterized molecular mechansisms, although putatively it acts by increasing central nervous system (CNS) concentrations of γ-aminobutryic acid (GABA), among other molecular neural effects. Identified as an enhancer of human embryonic stem cell (hES) self-renewal through a high-throughput screen assay, and confirmed to increase transcriptional levels of Nanog. The significance of autocrine GABAergic signaling endogenously in ES cells and its role in maintenance of ES self-renewal confirms a likely GABAergic mechanism for theanine activity in ES cells.
 * Flurbiprofen ( 2-(3-fluoro-4-phenyl-phenyl)propanoic acid ): Small-molecule compound that is a non-steroidal cyclooxgenase 2 (COX2) inhibitor, acting as an anti-inflammatory agent. Enhances human embryonic stem cell (hES) self-renewal through an unknown mechanism, as identified through high throughput-format screening. Molecular mechanisms remain ambiguous, but anti-inflammatory molecular mechanisms include but are not limited to: inhibition of protein and leukocyte migration, inhibition of prostaglandin synthesis, stabilization of the cell membrane, and activation of mitochondrial ATPase.

Neural stem cell self-renewal

 * ±-Sulpride ( N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide ): Small-molecule compound agonist of the D2 dopamine receptor, promoting neural stem cell proliferation and self-renewal, countering the antiproliferative phenotypic effects of D2 and D3 dopamine receptor agonist bromocriptine.
 * Hh-Ag1.2 ( 3-chloro-N-((4'-cyano-6-methoxybiphenyl-3-yl)methyl)-N-(4-(methylamino)cyclohexyl)benzo[b]thiophene-2-carboxamide ): Small-molecule agonist of Smo and is an agonist of hedgehog signaling.

Neuroectodermal differentiation

 * Phosphoserine ( 2-amino-3-phosphonooxy-propanoic acid ): Small-molecule orphan ligand for metabotropic glutamate receptor (mGluR4), identified to promote neural stem cell (NSC) differentiation to neurons and fate neurosphere differentiation to a neuronal lineage, as assayed by Tuj1 expression.
 * G-strophanthin ( 1β,3β,5β,11α,14,19-Hexahydroxycard-20(22)-enolide 3-(6-deoxy-α-L-mannopyranoside) ): Well-characterized cardiac glycoside derived through pharmacognosis that is a putative promoter of neural stem cell differentiation to a neuronal lineage.
 * L-AP4 ( L-(+)-2-Amino-4-phosphonobutyric acid ): Specific small-molecule agonist to the type III glutamate receptor family, including mGluR4, instructively directing neuronal differentiation of neural stem cells putatively through similar molecular mechanisms of phosphoserine. Identified through functional clustering.
 * G-strophanthin ( 1β,3β,5β,11α,14,19-Hexahydroxycard-20(22)-enolide 3-(6-deoxy-α-L-mannopyranoside) ): Well-characterized cardiac glycoside derived through pharmacognosis that is a putative promoter of neural stem cell differentiation to a neuronal lineage.
 * Endothall ( 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid ): Dicarboxylic acid that is a protein phosphatase 2A (PP2A) inhibitor and an insectile pesticide with low acute toxicity believed to be a putative promoter of neural stem cell differentiation to a neuronal lineage.
 * All-trans retinoic acid (ATRA): Potent endogenous small-molecule compound with endogenous biological targets with pleiotropic activity. During development, retinoic acid is involved in patterning the anterior-posterior (AP) axis in the mammalian and insectile body plan, inducing caudalization and neuralization during the early stages of development, with numerous other later roles, including expansion, proliferation, and self-renewal of various pancreatic progenitors.
 * Neuropathiazol ( ethyl 4-[methyl-(2-phenyl-1,3-thiazol-4-yl)amino]benzoate ): Small molecule chemical compound of the disubstituted 4-aminothiazole classification that is an organic sulfurous heterocyclic that chemically induces neuronal differentiation of adult hippocampal neural progenitor cells (HCN) and suppresses astrogliogenesis. Molecular mechanisms uncharacterized.
 * D-cysteine
 * D-phenylalanine

Mesodermal differentiation

 * QS11: 2,6,9-trisubstituted purine compound

Endodermal differentiation
Directed differentiation of embryonic stem (ES) cells to definitive endoderm (DE) lineage, believed to be canonically regulated with a threshold of Wnt signaling to specify plastic mesendoderm (ME), which is specified by TGFβ signals (Activin A, Nodal) to definitive endoderm, as assayed by SOX17 transcription factor expression and cytoskeletal marker Claudin-6 (Cldn-6).


 * BIO-Acetoxime ( [[(2Z)-2-(6-bromo-2-oxo-1H-indol-3-ylidene)indol-3-yl]amino] acetate ): Small molecule of the bis-indolo (indirubin) structural family that is a specific inhibitor of GSK3β, inducing stabilization of nuclear-localized β-catenin and artificial activation of Wnt/β-catenin signaling, inducing mesendodermal (ME) specification of embryonic stem (ES) cells and subsequent specification of anterior definitive endoderm (DE), as assayed by Brachyury, followed by FOXA2 and Cerberus-1 (CER1) expression, respectively.
 * Cymarin ( (3S,5S,8R,10S,13R,14S,17R)-5,14-dihydroxy-3-((2R,4S,5S,6R)-5-hydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yloxy)-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde : Pharmagnosis-derived secondary plant metabolite that is a Na+/K+ pump inhibitor, acting through unknown molecular mechanisms to strongly induce directed differentiation to the definitive endoderm lineage (as assayed by strong SOX17 expression), comparable to treatment with recombinant Activin A. Cardiac glycoside to increase cardiac contraction strength, is also is a cardiac mutagen and carcinogen.
 * Sarmentogenin ( 4-[(3S,5R,8R,9R,10S,11R,13R,14S,17S)-3,11,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one ): Steroid aglycon of sarmentocymarin, chemical analog digitoxigenin with a hydroxyl modification at organic position 11, acting through unknown molecular mechanisms to strongly induce directed differentiation to the definitive endoderm lineage (as assayed by strong SOX17 expression), comparable to treatment with recombinant Activin A. Similarly, is a cardiac glycoside.

Chemical Control of the Adult Psychology

 * (+)-WIN-55212: CB1 and CB2 cannabinoid receptor activator, described by Compton et. al (2002) to have an in vitro biological activity at a Ki of of 62.3 ± 31 nM for human CB1 and a Ki of 3.30 ± 0.40 nM for human CB2 against 0.5 nM [3H]CP 55940
 * 2C-E: substituted phenethylamine and presumptive dopamine active transporter (DAT) inhibitor
 * A-769662: 5' adenosine monophosphate-activated protein kinase (AMPK) activator, described by Cool et. al (2006) to have an in vivo biological activity at a dosage of 30 mg/kg and an in vitro biological activity at an IC50 of 3.2 μM
 * GW1516: peroxisome proliferator-activated receptor (PPARδ) activator, described by Sznaidmann et. al (2003) to have an in vitro transactivation activity at a concentration of 1.0 nM for human PPARδ
 * JZL184: monoacylglycerol lipase (MAGL) inhibitor that increases 2-arachidonoylglycerol (2-AG) transmission, described by Long et. al (2009) to have nearly-complete inhibitory activity at 1.0 nM
 * O-1783: dopamine active transporter (DAT) inhibitor, described by Meltzer et. al (2003) to have an IC50 of 17 nM competitively inhibits [3H]WIN 35,428 binding to the transporter in the rhesus monkey (Macaca mulatta)
 * Selegiline: monoamine oxide-B (MAOB) inhibitor, described by Engberg et. al (1991) to inhibit MAOB and increase dopa accumulation following 3-hydroxybenzyihydrazine administration at an in vivo concentration of 30mg/kg through intraperitoneal (I.P.) administration

Neurocytoarchitectonics

 * BPIQ-II: small-molecule chemical inhibitor of epidermal growth factor receptor (EGFR) that inhibits endogenous inhibition of axonal regeneration through myelin and chondroitin sulfate proteoglycans

Musculoskeletal and Metabolism

 * BMP7: 28.8 kDa homodimeric glycoprotein, which correspond to amino acid residues 316 to 431 of the full-length BMP7 precursor, solubilized in hydroxyapatite
 * Myf5-PRDM16shRNA: promoter-driven gene system ligated into non-replicative, transiently-expressed, non-integrating adenoviral expression vector for specific promoter-driven expression
 * Snai-MyoD: promoter-driven gene system built ligated non-replicative, transiently-expressed, non-integrating adenoviral expression vector for specific promoter-driven expression

Order of Battle

 * Command Element
 * Senior Commander: VADM Kawika Son (Vice Admiral, O-9)
 * Mobility Element
 * Detachment Commander: CAPT Raphael-064 (Captain, O-6)
 * Detachment Senior Enlisted: MCPO (Master Chief Petty Officer, E-9)
 * Alpha Squadron (Direct Action / Assault)
 * Alpha Squadron Commander: CMDR (Commander, O-5)
 * Squadron Senior Enlisted: CPO (Chief Petty Officer, E-7)
 * Alpha Squadron XO: LT (Lieutenant, O-3)
 * Squadron Operations Officer: LTJG (Lieutenant Jr. Grade, O-2)
 * Bravo Squadron (Direct Action / Assault)
 * Bravo Squadron Commander: CMDR (Commander, O-5)
 * Squadron Senior Enlisted: CPO (Chief Petty Officer, E-7)
 * Bravo Squadron XO: LT (Lieutenant, O-3)
 * Squadron Operations Officer: LTJG (Lieutenant Jr. Grade, O-2)
 * Charlie Squadron (Direct Action / Reconnaissance)
 * Charlie Squadron Commander: CMDR (Commander, O-5)
 * Squadron Senior Enlisted: CPO (Chief Petty Officer, E-7)
 * Charlie Squadron XO: LT (Lieutenant, O-3)
 * Squadron Operations Officer: LTJG (Lieutenant Jr. Grade, O-2)
 * Delta Squadron: (Direct Action / Covert Action)
 * Delta Squadron Commander: CMDR Florian-021 (Commander, O-5)
 * Squadron Senior Enlisted: CPO Eve-005 (Chief Petty Officer, E-7)
 * Delta Squadron XO: LT (Lieutenant, O-3)
 * Squadron Operations Officer: LTJG Bjorn-047 (Lieutenant Jr. Grade, O-2)
 * Team Loki
 * PO1 Alyssa-028 (Petty Officer 1st Class, E-6)
 * PO2 Gordon-055 (Petty Officer 2nd Class, E-5)
 * Team Valkyrie
 * CMDR Florian-021 (Commander, O-5) — Squadron commander
 * CPO Eve-005 (Chief Petty Officer, E-7) — Squadron leading petty officer
 * LTJG Bjorn-047 (Lieutenant Jr. Grade, O-2) — Squadron operations officer
 * PO2 Daphne-097 (Petty Officer 2nd Class, E-5)

Behind the Scenes

 * The Myrmidons are named after the Myrmidons of Greek mythology, another Greek warfighting tribe similar to the Spartans in ancient times.